PaxGenBio Accelerates Global Partnership Expansion through Participation in MEDICA 2025

PaxGenBio participated in the world’s largest medical device exhibition, MEDICA 2025, where the company showcased its MPCR-ULFA–based infectious disease diagnostic platform and global market strategy, further strengthening collaboration with overseas partners.

During the exhibition held at Messe Düsseldorf in Düsseldorf, Germany, PaxGenBio presented its key products and pipelines. Around 70 companies from approximately 40 countries across five continents visited the booth, showing strong interest in the company’s technologies and products.

MPCR-ULFA-Based Multiplex Diagnostic Portfolio Enhances Both Efficiency and Accessibility

At MEDICA 2025, PaxGenBio focused on presenting a wide range of infectious disease diagnostic kits based on its core MPCR-ULFA (Multiplex PCR–Universal Lateral Flow Assay) platform.

At the booth, the company highlighted the PaxView® STI 12 MPCR-ULFA Kit, which enables simultaneous detection of 12 sexually transmitted infections (STIs) in a single test; the PaxView® HPV Genotyping MPCR-ULFA series, which can analyze various genotypes of human papillomavirus (HPV), the main cause of cervical cancer; and the TB/NTM MPCR-ULFA Kit, designed for the detection of tuberculosis and nontuberculous mycobacterial infections. Through these solutions, PaxGenBio emphasized the advantages of multiplex molecular diagnostics, which can identify multiple targets in a single assay.

The MPCR-ULFA platform improves testing efficiency and diagnostic reliability through multiplex gene detection, while allowing results to be checked without the need for complex instruments. In particular, PaxGenBio showcased both a reader-free format for visual interpretation and a PaxView® ULFA Reader–linked solution, underscoring that the platform can be flexibly applied in resource-limited small- and mid-sized laboratories as well as in developing markets.

Expanding Diagnostic Workflow with Real-Time PCR Solutions

In addition to its MPCR-ULFA product line, PaxGenBio also presented real-time PCR–based molecular diagnostic products, further extending its diagnostic workflow.

The PaxView® STI12 FMCA (Fluorescence Melting Curve Analysis) Kit, a real-time PCR product, is designed to differentiate multiple pathogens using fluorescence melting curve analysis. This approach helps reduce testing time and cost compared to conventional single-target assays.

Expanding Global Network and Confirming Balanced Interest across Continents

At MEDICA 2025, PaxGenBio reconfirmed global demand for its technologies and products through booth visit statistics that showed well-balanced interest from partners across different continents.

In Europe, discussions centered on economical multiplex molecular diagnostic solutions suitable for small- and mid-sized laboratories, along with strategies for responding to IVDR regulations. In Asia, the Middle East, Africa, and Latin America, PaxGenBio exchanged a wide range of views on diagnostic needs for infectious diseases such as HPV, STIs, and TB/NTM, as well as on each country’s tender and registration structures, pricing policies, and supply models linked to public healthcare systems.

Based on the networks and market insights gained through this exhibition, PaxGenBio plans to gradually implement region-specific panel configurations, pricing strategies, and registration/regulatory support tailored to local disease patterns and healthcare infrastructure, thereby continuing to accelerate its global market share expansion.

Maximizing Diagnostic Efficiency in Clinical Settings with Innovative Molecular Solutions

MPCR-ULFA technology is an advanced system designed to detect multiple genes simultaneously in a single test by combining the strengths of molecular diagnostics and immunodiagnostics. This technology enables rapid and accurate detection of a wide range of infectious disease–related genes, supporting early diagnosis and appropriate treatment decisions in healthcare settings.

In addition, automatic analysis via the PaxView® ULFA Reader not only improves testing speed and accuracy, but also enhances the objectivity of result interpretation, helping reduce inter-operator variability. PaxGenBio emphasizes that, based on this technology, it is able to provide a “practical molecular diagnostic solution” that can be adopted without excessive burden even by small- and mid-sized laboratories.

PaxGenBio plans to further strengthen collaboration with distribution partners in Europe, Africa, Asia, the Middle East, and Latin America, and to expand R&D and clinical collaborations with selected partners to meet diverse diagnostic needs in the global bio market.

Meanwhile, PaxGenBio continues to solidify its position as a global bio company by developing innovative molecular and immunodiagnostic products aimed at contributing to early disease detection, prevention, and efficient infection control, and by supplying these solutions to healthcare institutions worldwide.